LEADER 03122nam  22004215  450 
001 9910337501503321
005 20200705115133.0
010   $a981-10-4548-8
024 7 $a10.1007/978-981-10-4548-6
035   $a(CKB)4100000005471895
035   $a(MiAaPQ)EBC5484909
035   $a(DE-He213)978-981-10-4548-6
035   $a(PPN)229499694
035   $a(EXLCZ)994100000005471895
100   $a20180731d2019      u|         0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aIgG4-Related Sclerosing Cholangitis /$fedited by Terumi Kamisawa, Myung-Hwan Kim
205   $a1st ed. 2019.
210  1$aSingapore :$cSpringer Singapore :$cImprint: Springer,$d2019.
215   $a1 online resource (141 pages)
311   $a981-10-4547-X 
327   $aO verview including classification of sclerosing cholangitis -- Epidemiology -- Pathophysiology -- Pathology -- Clinical features -- Serology -- Diagnostic criteria -- Imaging -- 1) US and CT -- 2) MRI with MRCP -- 3) ERCP -- 4) EUS and IDUS -- Differential diagnosis from primarysclerosing cholangitis -- Differential diagnosis from cholangiocarcinoma -- Tissue acquisition for histologic diagnosis -- Other organ involvements including autoimmune pancreatitis -- Treatment -- 1) Steroids -- 2) Immunomodulatory drugs -- 3) Rituximab -- Prognosis -- IgG4-related sclerosing cholangitis in America -- IgG4-related sclerosing cholangitis in Europe -- IgG4-related disease.
330   $aThis book aims to raise awareness of IgG4-related sclerosing cholangitis among practicing physicians and to equip readers with a sound understanding of the principles of diagnosis and treatment. Clinical, serological, and histopathological features are clearly described and imaging appearances on all relevant modalities are illustrated, covering the bile duct and other involved organs. Differential diagnosis from other diseases, including primary sclerosing cholangitis and cholangiocarcinoma, is precisely explained. Information is then presented on all significant current and emerging therapeutic strategies, including steroids, immunosuppressive drugs, and rituximab. Finally, attention is drawn to significant prognostic features. While IgG4-related sclerosing cholangitis is now a widely acknowledged condition, most practitioners are still liable to misdiagnose it owing to a lack of familiarity with its presenting features. This book should help to rectify the situation and will be an asset for all who may encounter the disease in clinical practice.
606   $aInternal medicine
606   $aInternal Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H33002
615  0$aInternal medicine.
615 14$aInternal Medicine.
676   $a612.35
702   $aKamisawa$b Terumi$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aKim$b Myung-Hwan$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910337501503321
996   $aIgG4-Related Sclerosing Cholangitis$91736111
997   $aUNINA